Allergy immunotherapy safety: location matters!

Abstract

Allergy immunotherapy is a highly effective therapy that has been used in the treatment of allergic rhinitis, asthma, and venom allergy for over a century. Subcutaneous immunotherapy (SCIT) is currently the only US Food and Drug Administration approved form of allergy immunotherapy. In this commentary, we address the safety issues that surround the location of care of SCIT administration in a supervised medical facility versus in the home or other medically unsupervised facility. Although analysis of the data suggests that SCIT has an excellent safety profile, we believe that this safety is largely due to the safety measures that are implemented when SCIT is administered in a medically supervised setting with appropriate staff and equipment to immediately recognize and treat anaphylaxis. In the home or medically unsupervised setting, the preinjection health assessment may not be adequate and access to immediate emergency medical treatment is unlikely to occur. We strongly urge all health care providers to adhere to the current Allergy Immunotherapy Practice Parameter recommendations and that patients be appropriately assessed before and monitored after allergy immunotherapy injections in a medically supervised facility.

Keywords: Allergy immunotherapy; Anaphylaxis; Desensitization; Subcutaneous immunotherapy; immunologic.